Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01322
|
|||||
| Drug Name |
Cilostazol
|
|||||
| Synonyms |
Cilostazole; 3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril; 6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril; 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one; 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone; 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one; 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one; 73963-72-1; BRN 3632107; C 0737; C20H27N5O2; CHEBI:31401; CL23867; Cilostazol (JP15/USAN/INN); Cilostazol [INN:JAN]; Cilostazole; Cilostazolum; Cilostazolum [INN-Latin]; MLS000028470; OPC 13013; OPC 21; OPC-13013; OPC-21; Otsuka brand of cilostazol; Pleta (TN); Pletaal; Pletal; Pletal (TN); Pletal, Cilostazol; UNII-N7Z035406B; cilostazol
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Intermittent claudication [ICD11:BD40.00] | Approved | [1] | |||
| Therapeutic Class |
Vasodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H27N5O2
|
|||||
| Canonical SMILES |
C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
|
|||||
| InChI |
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
|
|||||
| InChIKey |
RRGUKTPIGVIEKM-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 73963-72-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 369.5 | Topological Polar Surface Area | 81.9 | ||
| Heavy Atom Count | 27 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
855683
,6897916
,7848958
,7978527
,8151779
,11110906
,11113335
,11372358
,11374323
,11484992
,11488934
,11490985
,11492587
,11528739
,12012700
,14755273
,14828756
,17404781
,24278291
,26612838
,26680450
,26719653
,26719654
,26746958
,26746959
,29221909
,46386747
,46386994
,46506317
,47365365
,48259412
,48259413
,49834949
,50100194
,50103999
,50104000
,50409718
,53777324
,53787948
,56422089
,56463107
,57321435
,68530811
,85230957
,85787626
,87218800
,87218801
,87219014
,90341176
,92124839
|
|||||
| ChEBI ID |
CHEBI:29007
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [2] | |
| OATP1B1 | Transporter Info | Organic anion transporting polypeptide 1B1 | Substrate | [3] | ||
| OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | OATP1B1 | Transporter Info | Km =17.7 microM | Human embryonic kidney cells (HEK293)-OATP1B1 | [3] | |
| OATP1B3 | Transporter Info | Km =2.7 microM | Human embryonic kidney cells (HEK293)-OATP1B3 | [3] | ||
| References | ||||||
| 1 | Cilostazol was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007. | |||||
| 3 | Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.